Clinical Trial

Phase II Dutasteride in Combination With CAB vs CAB in SDC

Study acronym: DUCT
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 4, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
Phase 2 clinical trial on the addition of dutasteride to combined androgen blockade (CAB) therapy in recurrent and/or metastatic (R/M) salivary duct carcinoma (SDC) patients. The study included two cohorts of patients: Cohort A, which comprises ADT-naïve patients, and Cohort B, which comprises ADT-resistant patients. Cohort A is closed for inclusion as of April 18, 2024.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-08-23; most recent amendment 2025-06-03.
Status change: Not Yet Recruiting → Recruiting 2022-09-21
Trial Details
NCT Number NCT05513365
Lead Sponsor Radboud University Medical Center
Collaborators: ZonMw: The Netherlands Organisation for Health Research and Development
Conditions Salivary Duct Carcinoma
Enrollment 26 participants
Start Date 2022-09-27
Primary Completion 2025-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2025-06-04